Pharma BD Deal Intelligence

Ferrer Internacional S.A. / Verge Genomics

2024 · Co-Development · $122M · Complete

On 25 March 2024, Verge Genomics and Ferrer announced a strategic collaboration to co-develop VRG50635 for sporadic and familial amyotrophic lateral sclerosis (ALS). Ferrer received exclusive co-development and commercialization rights in Europe, Central and South America, Southeast Asia and Japan, while Verge retained United States rights and rights in other territories. Ferrer committed more than EUR 112.5 million (approximately US$121.7 million) in combined upfront and potential development and commercial milestone payments, plus royalties on future sales. VRG50635 is a small-molecule PIKfyve inhibitor discovered using Verge's CONVERGE all-in-human platform and was in Phase 1b proof-of-concept studies in Canada and several European countries at signing.

Key facts

• Announced Mar 25, 2024
• Deal value $122M
• Deal type Co-Development

Related deals

• Nuvation Bio Inc. / AnHeart Therapeutics, Ltd. (2024)
• Novo Holdings A/S / Catalent (manufacturing sites) (2024)
• Novartis AG / PTC Therapeutics Inc. (2024)
• Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences (2024)
• Johnson & Johnson / Shockwave Medical (2024)
• Gilead Sciences Inc. / CymaBay Therapeutics (2024)

← Browse all deals  ·  How we score deals

More: 2024 deals